Search results for "Bleeding risk"
Ticagrelor monotherapy associated with less bleeding risk than dual antiplatelet therapy
In patients with acute coronary syndrome who received drug-eluting stents, ischemic outcomes did not differ with continued dual antiplatelet therapy versus de-escalation after a few weeks and up to three months to ticagrelor monotherapy, while bleeding risk was lower with the latter, according to a meta-analysis.
https://immattersacp.org/weekly/archives/2025/02/18/1.htm
18 Feb 2025
MKSAP Quiz: Medication after STEMI
A 69-year-old man is evaluated in the hospital 3 days after presenting with chest pain due to an acute inferior wall ST-elevation myocardial infarction (STEMI). He underwent urgent coronary angiography and successful drug-eluting stent placement. What is the most appropriate antithrombotic treatment strategy?
https://immattersacp.org/weekly/archives/2025/02/11/3.htm
11 Feb 2025
NOACs, aspirin carry similar risks of major bleeding, intracranial hemorrhage
Risks of major bleeding and intracranial hemorrhage were similar with therapeutic doses of the non-vitamin K oral anticoagulants (NOACs) apixaban and dabigatran versus with aspirin, a review of nine trials with more than 26,000 participants found.
https://immattersacp.org/weekly/archives/2025/02/11/1.htm
11 Feb 2025
Long-term anticoagulation after first unprovoked VTE associated with considerable bleeding risk
Results from a systematic review and meta-analysis provide a framework for clinicians and patients to balance the benefits and harms of extended anticoagulation for unprovoked venous thromboembolism (VTE).
https://immattersacp.org/weekly/archives/2021/09/14/4.htm
14 Sep 2021
Diltiazem may increase bleeding risk when coadministered with DOACs in afib
A study of patients with atrial fibrillation in one U.S. health system found a 56% higher risk for bleeding-related hospitalization associated with concomitant use of diltiazem and a direct-acting oral anticoagulant (DOAC) versus a DOAC alone.
https://immattersacp.org/weekly/archives/2022/07/12/5.htm
12 Jul 2022
MKSAP Quiz: Treatment of deep venous thrombosis
A 55-year-old woman is evaluated in the emergency department for right leg swelling and is diagnosed with a proximal deep venous thrombosis. Medical history is significant for end-stage kidney disease for which she is undergoing hemodialysis. What is the most appropriate anticoagulation treatment?
https://immattersacp.org/weekly/archives/2024/11/26/3.htm
26 Nov 2024
Dual therapy for afib after PCI may reduce bleeding risk better than triple therapy
Researchers reviewed four randomized controlled trials of 7,953 patients that compared the effects of dual versus triple therapy on bleeding, mortality, and ischemic events after percutaneous coronary intervention (PCI).
https://immattersacp.org/weekly/archives/2020/03/17/4.htm
17 Mar 2020
Bleeding risk of dabigatran under scrutiny
Serious bleeding events have been reported in patients taking dabigatran (Pradaxa), according to a new FDA MedWatch alert.
https://immattersacp.org/weekly/archives/2011/12/13/7.htm
13 Dec 2011
Anticoagulation not superior to placebo for calf DVT in low-risk patients, may increase bleeding risk
The randomized, double-blind, placebo-controlled trial examined a composite measure of extension of calf deep venous thrombosis (DVT) to proximal veins, contralateral proximal DVT, and symptomatic pulmonary embolism in a modified intention-to-treat population.
https://immattersacp.org/weekly/archives/2016/11/15/6.htm
15 Nov 2016
Lifestyle, treatment changes for afib
A new atrial fibrillation guideline focuses on early rhythm control and lifestyle changes such as physical activity and weight loss to slow or disrupt the course of the disease.
https://immattersacp.org/archives/2024/09/lifestyle-treatment-changes-for-afib.htm
1 Sep 2024